Veradermics, Incorporated (NYSE:MANE – Get Free Report)’s share price was down 4.4% during mid-day trading on Monday . The company traded as low as $98.26 and last traded at $100.3570. Approximately 561,446 shares changed hands during mid-day trading, a decline of 1% from the average session volume of 567,439 shares. The stock had previously closed at $105.00.
Wall Street Analyst Weigh In
Several brokerages have weighed in on MANE. Lifesci Capital began coverage on shares of Veradermics in a research note on Tuesday, June 16th. They issued an “outperform” rating and a $135.00 price objective for the company. Needham & Company LLC raised their target price on shares of Veradermics from $136.00 to $164.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Jefferies Financial Group increased their price target on Veradermics from $138.00 to $182.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Citigroup lifted their price objective on Veradermics from $135.00 to $160.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Finally, Leerink Partners boosted their price target on Veradermics from $75.00 to $90.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $153.00.
View Our Latest Analysis on Veradermics
Veradermics Trading Down 8.7%
Veradermics (NYSE:MANE – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.76).
Veradermics Company Profile
We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.
Further Reading
- Five stocks we like better than Veradermics
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Veradermics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veradermics and related companies with MarketBeat.com's FREE daily email newsletter.
